Advertisement

FDA Advisers: Meta-Analysis Does Not Prove That Naproxen Carries Lower CV Risk — Physician’s First Watch

Medical News |
February 12, 2014

FDA Advisers: Meta-Analysis Does Not Prove That Naproxen Carries Lower CV Risk

By Amy Orciari Herman

Data from a meta-analysis suggesting that naproxen carries lower cardiovascular risk than other nonsteroidal anti-inflammatory drugs are not reliable, FDA advisers concluded on Tuesday. Consequently, they voted that naproxen should not get a new label based on those data, Reuters reports.

The meta-analysis, published in the Lancet in 2013, found that coxibs or diclofenac conferred increased risk for major vascular events, and ibuprofen showed increased risk for coronary events, relative to placebo. Meanwhile, no such risk increases were seen with naproxen.

The FDA advisers recommended that naproxen's prescribing information stay as is until data from the PRECISION trial are available. That large, randomized trial is comparing naproxen with celecoxib or ibuprofen in patients with osteoarthritis or rheumatoid arthritis.

Reader Comments (1)

blessing Preventive Medicine

how to make a cv?

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement